To keep up with the latest from FIP, follow us on social media!
A wide range of opportunities for pharmacists to provide cardiovascular disease (CVD) services are described in a new practice support handbook published by FIP today. According to the World Health Organization, deaths from CVDs currently represent 32% of all deaths globally, with over 75% of these occurring in low- and middle-income countries. With deaths from CVDs projected to increase from 18.9 million in 2020 to 32.3 million by 2030, demand for cardiovascular prevention, care and treatments continues to grow. “Cardiovascular diseases: A handbook for pharmacists” covers prevention, care and management roles, including: health promotion and education; early detection; triage and referral; interprofessional collaborative practice; disease management (including medication adherence); treatment optimisation; and helping to shape public policies. In particular, it contains a chapter on practice-based research.
“Care goes beyond medicines use and optimising effectiveness and safety. Pharmacists can also be involved in practice-based research to evaluate the impact of CVD services. This new handbook contains several evidence-based interventions by pharmacists around the world that have led to positive health and economic outcomes for patients, which readers will find valuable and inspirational,” said Inês Nunes da Cunha, FIP practice development and transformation projects manager and lead author of the handbook. “It is important that pharmacists are able to meet needs, expanding and consolidating their CVD services and roles with the appropriate knowledge and skills as defined in the ‘FIP Knowledge and skills reference guide for professional development in cardiovascular diseases’ [also published by FIP today]. It is also essential that pharmacy professional organisations at global, regional and national levels support practitioners in implementing and providing services in this area,” she said.
The new handbook has been developed in collaboration with the World Heart Federation (WHF) and the European Society of Clinical Pharmacy.